Incyte drops on updated epacadostat data

Incyte Corp. (NASDAQ:INCY) fell $16.55 (14%) to $100.21 on Friday after new data from a Phase I/II trial of its epacadostat plus Keytruda pembrolizumab to treat advanced cancers showed lower response rates than earlier data from the study.

At the Society for Immunotherapy of Cancer meeting in National Harbor, Md., study investigator Tara Gangadhar of the University of Pennsylvania reported a disease control rate (DCR) of 68% and an overall response rate (ORR) of 38% in 47 evaluable patients across seven cancer types. ...